Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Senescence impairs successful reprogramming to pluripotent stem cells.

Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J.

Genes Dev. 2009 Sep 15;23(18):2134-9. doi: 10.1101/gad.1811609. Epub 2009 Aug 20.

2.

Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.

Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K.

Nature. 2009 Aug 27;460(7259):1145-8. doi: 10.1038/nature08285. Epub 2009 Aug 9.

3.

The Ink4/Arf locus is a barrier for iPS cell reprogramming.

Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M.

Nature. 2009 Aug 27;460(7259):1136-9. doi: 10.1038/nature08290. Epub 2009 Aug 9.

4.

Linking the p53 tumour suppressor pathway to somatic cell reprogramming.

Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisúa Belmonte JC.

Nature. 2009 Aug 27;460(7259):1140-4. doi: 10.1038/nature08311. Epub 2009 Aug 9.

5.

Genome instability, cancer and aging.

Maslov AY, Vijg J.

Biochim Biophys Acta. 2009 Oct;1790(10):963-9. doi: 10.1016/j.bbagen.2009.03.020. Epub 2009 Mar 31. Review.

6.

Mutational spectra of human cancer.

Pfeifer GP, Besaratinia A.

Hum Genet. 2009 Jun;125(5-6):493-506. doi: 10.1007/s00439-009-0657-2. Epub 2009 Mar 24. Review.

7.

p53 polymorphisms: cancer implications.

Whibley C, Pharoah PD, Hollstein M.

Nat Rev Cancer. 2009 Feb;9(2):95-107. doi: 10.1038/nrc2584. Review.

PMID:
19165225
8.

Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis.

Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N.

Cancer Cell. 2008 Dec 9;14(6):458-70. doi: 10.1016/j.ccr.2008.11.003.

9.

TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours.

Nedelko T, Arlt VM, Phillips DH, Hollstein M.

Int J Cancer. 2009 Feb 15;124(4):987-90. doi: 10.1002/ijc.24006.

10.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW.

Science. 2008 Sep 26;321(5897):1801-6. doi: 10.1126/science.1164368. Epub 2008 Sep 4.

11.

The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences.

vom Brocke J, Krais A, Whibley C, Hollstein MC, Schmeiser HH.

Mutagenesis. 2009 Jan;24(1):17-23. doi: 10.1093/mutage/gen049. Epub 2008 Sep 2.

PMID:
18765419
12.

The Arf/p53 pathway in cancer and aging.

Matheu A, Maraver A, Serrano M.

Cancer Res. 2008 Aug 1;68(15):6031-4. doi: 10.1158/0008-5472.CAN-07-6851. Review.

13.

Knockin mice expressing a chimeric p53 protein reveal mechanistic differences in how p53 triggers apoptosis and senescence.

Johnson TM, Meade K, Pathak N, Marques MR, Attardi LD.

Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1215-20. doi: 10.1073/pnas.0706764105. Epub 2008 Jan 23.

14.

Common tumour p53 mutations in immortalized cells from Hupki mice heterozygous at codon 72.

Reinbold M, Luo JL, Nedelko T, Jerchow B, Murphy ME, Whibley C, Wei Q, Hollstein M.

Oncogene. 2008 Apr 24;27(19):2788-94. Epub 2007 Nov 12.

PMID:
17998932
15.

Cellular senescence bypass screen identifies new putative tumor suppressor genes.

Leal JF, Fominaya J, Cascón A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon Y Cajal S, Robledo M, Beach DH, Carnero A.

Oncogene. 2008 Mar 27;27(14):1961-70. Epub 2007 Oct 29.

PMID:
17968325
16.

Cellular senescence in cancer and aging.

Collado M, Blasco MA, Serrano M.

Cell. 2007 Jul 27;130(2):223-33. Review.

17.

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

Song H, Hollstein M, Xu Y.

Nat Cell Biol. 2007 May;9(5):573-80. Epub 2007 Apr 8.

PMID:
17417627
18.

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.

Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M.

Hum Mutat. 2007 Jun;28(6):622-9.

PMID:
17311302
19.

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW.

Nature. 2007 Feb 8;445(7128):656-60. Epub 2007 Jan 24. Erratum in: Nature. 2011 May 26;473(7348):544.

20.

Modeling the therapeutic efficacy of p53 restoration in tumors.

Martins CP, Brown-Swigart L, Evan GI.

Cell. 2006 Dec 29;127(7):1323-34. Epub 2006 Dec 21.

Supplemental Content

Support Center